“Hot Flashes Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Hot Flashes Market.
The Hot Flashes Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.
The report provides insights into:
-
The report provides detailed insights into the emerging therapies for the treatment of Hot Flashes and the aggregate therapies developed by major pharma companies.
-
It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.
-
It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
-
The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
-
It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Hot Flashes market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, featured press releases from company/university websites, industry-specific third-party sources, etc.
Analysis of Emerging Therapies by Phases
The report covers the emerging products under different phases of clinical development like –
-
Late-stage products (Phase III)
-
Mid-stage products (Phase II)
-
Early-stage product (Phase I)
-
Pre-clinical and Discovery stage candidates
-
Discontinued & Inactive candidates
Route of Administration
Hot Flashes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Oral
-
Intravenous
-
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
-
Small molecule
-
Thiadiazoles
-
Recombinant proteins
Learn How the Ongoing Clinical & Commercial Activities will Affect the Hot Flashes Therapeutic Segment @
https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight
Hot Flashes Therapeutics Landscape
There are approx. 15+ key companies developing therapies for Hot Flashes. Currently, Veru Inc. is leading the therapeutics market with its Hot Flashes drug candidates in the most advanced stage of clinical development.
The Leading Companies in the Hot Flashes Therapeutics Market Include:
-
Veru Healthcare
-
Fervent Pharmaceuticals
-
Ogeda
-
Bayer
-
Lundbeck A/S
-
TherapeuticsMD
-
MenoGeniX
-
Mitsubishi Tanabe Pharma
-
QUE Oncology
-
Pherin Pharmaceuticals
And Many Others
Hot Flashes Emerging and Marketed Drugs Covered in the Report Include:
-
Fezolinetant: Astellas Pharma
-
Elinzanetant: Bayer
-
Fezolinetant: Ogeda
-
Zuclomiphene citrate: Veru Inc
-
TX-001HR: TherapeuticsMD
-
BHR-401: Besins Healthcare
-
Donesta: Mithra Pharmaceuticals
-
Salubrin (PH-80): Pherin Pharmaceuticals
-
Fezolinetant (ESN364): Ogeda/Astellas
-
NT-814: Nerre Therapeutics
And Many More
Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @
https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight
Table of Content (TOC)
1. Report Introduction
2. Executive Summary
3. Hot Flashes Current Treatment Patterns
4. Hot Flashes – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Hot Flashes Late Stage Products (Phase-III)
7. Hot Flashes Mid-Stage Products (Phase-II)
8. Hot Flashes Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hot Flashes Discontinued Products
13. Hot Flashes Product Profiles
14. Key Companies in the Hot Flashes Market
15. Key Products in the Hot Flashes Therapeutics Segment
16. Dormant and Discontinued Products
17. Hot Flashes Unmet Needs
18. Hot Flashes Future Perspectives
19. Hot Flashes Analyst Review
20. Appendix
21. Report Methodology
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/hot-flashes-pipeline-insight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Pars Plantis market trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan). Moreover, it covers the current treatment practices, emerging drugs, market share of individual therapies, treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Pars Plantis market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/